Miske, Ramona
Scharf, Madeleine
Borowski, Kathrin
Rieckhoff, Nicole
Teegen, Bianca
Denno, Yvonne
Probst, Christian
Guthke, Kersten
Didrihsone, Ieva
Wildemann, Brigitte
Ruprecht, Klemens
Komorowski, Lars
Jarius, Sven
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 2 November 2022
Accepted: 3 February 2023
First Online: 30 March 2023
Declarations
:
: All septin-3-IgG-positive serum and CSF samples were obtained and sent in for routine diagnostic antibody identification. All patients gave written informed consent for publication. The use of the control sera provided by the Department of Neurology, Charité, Berlin, was approved by the ethics committee of Charité–Universitätsmedizin Berlin (EA4/231/20 and EA4/018/17).
: The patients gave written informed consent for publication.
: KB, BT, NR, SJ, KG, and ID have nothing to disclose. MS, RM, YD, CP, and LK are employees of EUROIMMUN. MS, RM, YD, and LK have septin-3 and -7 patent applications pending. KR received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program), Arthur Arnstein Foundation and Guthy Jackson Charitable Foundation. BW received grants from the German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, Klaus Tschira Foundation, grants and personal fees from Merck, and personal fees from Alexion, Bayer, Biogen, Roche, none related to this work.